MicroRNAs and androgen receptor 3′ untranslated region: A missing link in castration-resistant prostate cancer?

Molecular and Cellular Pharmacology

Volumn 3, Issue 3, 2011, Pages 107-113

  Sikand, Kavleen ^a,b   Barik, Sailen ^a   Shukla, Girish C ^a  

^a CLEVELAND STATE UNIVERSITY   (United States)

^b POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

3 UTR; Androgen receptor; miRNA; miRNA therapeutics; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; MICRORNA; MIR 488; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BASE PAIRING; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; DOWN REGULATION; DRUG RECEPTOR BINDING; GENE TARGETING; GENETIC REGULATION; HUMAN; MOLECULAR MECHANICS; MOLECULARLY TARGETED THERAPY; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION;

EID: 84855469522     PISSN: None     EISSN: 19381247     Source Type: Journal    
DOI: 10.4255/mcpharmacol.11.15     Document Type: Article

References (46)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Taneja SS. A multidisciplinary approach to the management of hormone-refractory prostate cancer. Rev Urol 2003;5 Suppl2:S53-S59.
3. Knudsen KE, Scher HI. Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res 2009;15:4792-8.
4. Mangelsdorf DJ, Thummel C, Beato M, et al. The nuclear receptor superfamily: the second decade. Cell 1995;83:835-9.
5. Brinkmann AO, Blok LJ, De Ruiter PE, et al. Mechanisms of androgen receptor activation and function. J Steroid Biochem Mol Biol 1999;69:307-13.
6. Dehm SM, Tindall DJ. Androgen receptor structural and functional elements: role and regulation in prostate cancer. Mol Endocrinol 2007;21:2855-63.
7. Heemers HV, Tindall DJ. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev 2007;28:778-808.
8. Buchanan G, Irvine RA, Coetzee GA, Tilley WD. Contribution of the androgen receptor to prostate cancer predisposition and progression. Cancer Metastasis Rev 2001;20:207-23.
9. Feldman BJ, Feldman D. The development of androgen- independent prostate cancer. Nat Rev Cancer 2001;1:34-45.
10. Pienta KJ, Bradley D. Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 2006;12:1665-71.
11. Chen Y, Sawyers CL, Scher HI. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 2008;8:440-8.
12. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-9.
13. Edwards J, Krishna NS, Grigor KM, Bartlett JM. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 2003;89:552-6.
14. Holzbeierlein J, Lal P, LaTulippe E, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004;164:217-27.
15. Stanbrough M, Bubley GJ, Ross K, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006;66:2815-25.
16. Farh KK, Grimson A, Jan C, et al. The widespread impact of mammalian MicroRNAs on mRNA repression and evolution. Science 2005;310:1817-21.
17. Sood P, Krek A, Zavolan M, Macino G, Rajewsky N. Cell-type-specific signatures of microRNAs on target mRNA expression. Proc Natl Acad Sci U S A 2006;103:2746-51.
18. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009;10:704-14.
19. Di LG, Croce CM. Roles of small RNAs in tumor formation. Trends Mol Med 2010;16:257-67.
20. Valeri N, Vannini I, Fanini F, Calore F, Adair B, Fabbri M. Epigenetics, miRNAs, and human cancer: a new chapter in human gene regulation. Mamm Genome 2009;20:573-80.
21. Weber B, Stresemann C, Brueckner B, Lyko F. Methylation of human microRNA genes in normal and neoplastic cells. Cell Cycle 2007;6:1001-5.
22. Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol 2009;27:5848-56.
23. Galardi S, Mercatelli N, Giorda E, et al. MiR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem 2007;282:23716-24.
24. Shi XB, Xue L, Yang J, et al. An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc Natl Acad Sci U S A 2007;104:19983-8.
25. Musiyenko A, Bitko V, Barik S. Ectopic expression of miR-126*, an intronic product of the vascular endothelial EGF-like 7 gene, regulates prostein translation and invasiveness of prostate cancer LNCaP cells. J Mol Med 2008;86:313-22.
26. Lin SL, Chiang A, Chang D, Ying SY. Loss of mir-146a function in hormone-refractory prostate cancer. RNA 2008;14:417-24.
27. Lee KH, Chen YL, Yeh SD, et al. MicroRNA-330 acts as tumor suppressor and induces apoptosis of prostate cancer cells through E2F1-mediated suppression of Akt phosphorylation. Oncogene 2009;28:3360-70.
28. Noonan EJ, Place RF, Pookot D, et al. miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene 2009;28:1714-24.
29. Fujita Y, Kojima K, Ohhashi R, et al. MiR-148a attenuates paclitaxel-resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression. J Biol Chem 2010;285:19076-84.
30. Epis MR, Giles KM, Barker A, Kendrick TS, Leedman PJ. MiR-331-3p regulates ERBB-2 expression and androgen receptor signaling in prostate cancer. J Biol Chem 2009;284:24696-704.
31. Ribas J, Ni X, Haffner M, et al. MiR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res 2009;69:7165-9.
32. Waltering KK, Porkka KP, Jalava SE, et al. Androgen regulation of micro-RNAs in prostate cancer. Prostate 2011;71:604-14.
33. Sikand K, Slaibi JE, Singh R, Slane SD, Shukla GC. MiR 488* inhibits androgen receptor expression in prostate carcinoma cells. Int J Cancer 2011;129:810-9.
34. Ostling P, Leivonen SK, Aakula A, et al. Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells. Cancer Res 2011;71:1956-67.
35. Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP. The impact of microRNAs on protein output. Nature 2008;455:64-71.
36. Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N. Widespread changes in protein synthesis induced by microRNAs. Nature 2008;455:58-63.
37. Faber PW, van Rooij HC, van der Korput HA, et al. Characterization of the human androgen receptor transcription unit. J Biol Chem 1991;266:10743-9.
38. Waltering KK, Wallen MJ, Tammela TL, Vessella RL, Visakorpi T. Mutation screening of the androgen receptor promoter and untranslated regions in prostate cancer. Prostate 2006;66:1585-91.
39. Yeap BB, Voon DC, Vivian JP, et al. Novel binding of HuR and poly(C)-binding protein to a conserved UC-rich motif within the 3'-untranslated region of the androgen receptor messenger RNA. J Biol Chem 2002;277:27183-92.
40. Zhou H, Mazan-Mamczarz K, Martindale JL, et al. Post-transcriptional regulation of androgen receptor mRNA by an ErbB3 binding protein 1 in prostate cancer. Nucleic Acids Res 2010;38:3619-31.
41. Stark A, Brennecke J, Bushati N, Russell RB, Cohen SM. Animal MicroRNAs confer robustness to gene expression and have a significant impact on 3'UTR evolution. Cell 2005;123:1133-46.
42. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009;19:92-105.
43. Mayr C, Bartel DP. Widespread shortening of 3'UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells. Cell 2009;138:673-84.
44. Trapman J, Klaassen P, Kuiper GG, et al. Cloning, structure and expression of a cDNA encoding the human androgen receptor. Biochem Biophys Res Commun 1988;153:241-8.
45. Taplin ME. Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat Clin Pract Oncol 2007;4:236-44.
46. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002;167:948-51.